Patent US4397867A successfully refreshed from Google Patents.
US4397867A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of arthritic complaints
Assignee: Novartis Corp
•
Filing: 1982-06-15
•
Granted: 1983-08-09
•
Expires: 2002-06-15
Abstract
Abstract Rheumatoid arthritic and like diseases involving joint inflammation are treated by administering desferrioxamine in a therapeutically effective dosage over a prolonged period.
Inventors
- 👤 David R. Blake
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 11:14
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K9/00; A61K9/10; A61K9/127; A61P; A61P29/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
39 words
A method for the treatment of rheumatoid arthritic and like diseases involving joint inflammation, which comprises administering to patents in need of such administration desferrioxamine in a therapeutically effective dosage over a prolonged period sufficient to reduce joint inflammation.
Claim 2
Independent Claim
39 words
A method for the treatment of rheumatoid arthritic and like diseases involving joint inflammation, which comprises administering to patents in need of such administration desferrioxamine in a therapeutically effective dosage over a prolonged period sufficient to reduce joint inflammation.
Claim 3
Dependent Claim
22 words
A method as claimed in claim 1 in which the amount of desferrioxamine administered is from 1 to 10 g per day.
Claim 4
Dependent Claim
22 words
A method as claimed in claim 2 in which the amount of desferrioxamine administered is from 2 to 3 g per day.
Claim 5
Independent Claim
23 words
A method as claimed in any one of claims 1 to 5 in which the period of administration is at least 15 days.
Claim 6
Dependent Claim
18 words
A method as claimed in claim 4 in which the period of administration is at least 3 weeks.
Claim 7
Independent Claim
25 words
A method as claimed in any one of claims 1 to 5 in which the desferrioxamine is administered intravenously, intraperitoneally, subcutaneously, intramuscularly, intraarticularly or transdermally.
Claim 8
Independent Claim
36 words
A method as claimed in any one of claims 1 to 5 in which the desferrioxamine is administered orally or parenterally in the form f a liposome formulation wherein the desferrioxamine is encapsulated in lipoid vesicles.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-08-08 | 1987-02-07 | 1987-08-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-08-08 | 1991-02-07 | 1991-08-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-08-08 | 1995-02-07 | 1995-08-09 | $7700.00 | Window Closed / Lapsed |